Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.

Abstract

INTRODUCTION:

Prophylaxis with plasma-derived or recombinant activated factor VII is beneficial in severe factor VII deficiency. To understand why prophylactic treatment with both products is efficacious, we conducted a pharmacokinetic study.

MATERIALS AND METHODS:

Ten factor VII deficient patients were treated with either recombinant activated (20 μg/kg) or plasma-derived (25 IU/kg) factor VII in a cross-over design. Pharmacokinetic parameters were analyzed through activated factor VII activity, factor VII clotting activity, and factor VII antigen levels on depicted time points.

RESULTS:

Factor VII activity half-lifes, determined by non-compartmental and one-compartmental analysis (results in brackets), were shorter for recombinant activated (1.4h; 0.7h) than for plasma-derived factor VII (6.8h; 3.2h); both recombinant activated (5.1h; 2.1h and plasma-derived factor VII (5.8h; 3.2h) resulted in longer half-lives of factor VII antigen. Activated factor VII half-lives (based on activated factor VII activity levels) were significantly higher compared to factor VII clotting activity (1.6h; 0.9h). Volumes of distribution were significantly higher for activated factor VII (236 ml/kg; 175 ml/kg, measured by activated factor VII) as compared to plasma-derived factor VII (206 ml/kg; 64 ml/kg, measured by factor FVII activity), suggesting a plasma- and extracellular fluid distribution for recombinant activated factor VII.

CONCLUSIONS:

Recombinant activated factor VII showed significantly shorter half-lifes than plasma-derived factor VII. Volumes of distribution were significantly higher for treatment with recombinant activated factor VII. The longer half-life for plasma-derived factor VII, compared to recombinant activated factor VII, and the increased volume of distribution for recombinant activated factor VII, compared to plasma-derived factor VII may further elucidate the beneficial effect of prophylactic treatment of both products.

• Authors: Natascha C J Mathijssen, Rosalinde Masereeuw, Pal Andre Holme, Marian G J van Kraaij, Britta A P Laros-van Gorkom, Flora Peyvandi, Waander L van Heerde
• Journal: Thrombosis research (Thromb Res) Vol. 132 Issue 2 Pg. 256-62 (Aug 2013) ISSN: 1879-2472 [Electronic] United States
• PMID: 23834817 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Recombinant Proteins
• Factor VIIa

Topics

• Adult
• Blood Coagulation Tests
• Cross-Over Studies
• Factor VII Deficiency (blood, drug therapy)
• Factor VIIa (pharmacokinetics, therapeutic use)
• Female
• Half-Life
• Hemostasis
• Humans
• Male
• Middle Aged
• Recombinant Proteins (blood, pharmacokinetics, therapeutic use)
• Young Adult